Gain Therapeutics Inc., a clinical-stage biotechnology company, has announced its intention to offer shares of its common stock and warrants in an underwritten public offering, as detailed in a prospectus filed with the SEC. The company plans to use the proceeds to advance the development of its lead product candidate, GT-02287, aimed at treating neurodegenerative diseases like GBA1 Parkinson's disease. Newbridge Securities Corporation is serving as the sole book-running manager for the offering. The specific terms and timing of the offering will depend on market conditions, and a preliminary prospectus supplement will be made available through the SEC's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.